Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR3.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR2.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR5.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR7.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR9.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR4.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR1.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR6.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR30.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR14.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR37.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR46.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR41.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR12.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR36.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR47.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR28.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR29.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR35.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR26.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR17.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR45.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR13.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR48.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR33.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR49.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR23.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR39.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR32.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR19.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR40.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR11.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR16.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR44.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR22.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR18.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR42.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR21.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR34.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR43.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR15.htm
EX-31.2 - EX-31.2 - ARIAD PHARMACEUTICALS INCd413091dex312.htm
EX-32.1 - EX-32.1 - ARIAD PHARMACEUTICALS INCd413091dex321.htm
EX-31.1 - EX-31.1 - ARIAD PHARMACEUTICALS INCd413091dex311.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR20.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR27.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR10.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR38.htm
10-Q - 10-Q - ARIAD PHARMACEUTICALS INCd413091d10q.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR8.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR24.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR31.htm
v2.4.0.6
Stock-Based Compensation (Tables)
9 Months Ended
Sep. 30, 2012
Total Compensation Cost from Share-Based Payments

The Company’s statement of operations included total compensation cost from share-based payments for the three and nine-month periods ended September 30, 2012 and 2011, as follows:

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
In thousands    2012      2011      2012      2011  

Compensation cost from:

           

Stock options

   $ 2,084       $ 609       $ 6,776       $ 2,215   

Stock and stock units

     1,697         971         5,343         3,589   

Purchases of common stock at a discount

     64         53         170         150   
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 3,845       $ 1,633       $ 12,289       $ 5,954   
  

 

 

    

 

 

    

 

 

    

 

 

 

Compensation cost included in:

           

Research and development expenses

   $ 1,869       $ 822       $ 6,060       $ 2,927   

General and administrative expenses

     1,976         811         6,229         3,027   
  

 

 

    

 

 

    

 

 

    

 

 

 
   $ 3,845       $ 1,633       $ 12,289       $ 5,954   
  

 

 

    

 

 

    

 

 

    

 

 

 
Stock Option Activity

Stock option activity under the Company’s stock plans for the nine months ended September 30, 2012 was as follows:

 

     Number of
Shares
    Weighted
Average

Exercise  Price
Per Share
 

Options outstanding, January 1, 2012

     7,381,329      $ 5.22   

Granted

     1,941,750      $ 15.36   

Forfeited

     (38,563   $ 11.91   

Exercised

     (1,737,863   $ 4.49   
  

 

 

   

Options outstanding, September 30, 2012

     7,546,653      $ 7.96   
  

 

 

   
Stock and stock units
 
Stock and Stock Unit Activity

Stock and stock unit activity under the Company’s stock plans for the nine months ended September 30, 2012 was as follows:

 

     Number of
Shares
    Weighted
Average

Grant  Date
Fair Value
 

Outstanding, January 1, 2012

     2,785,026      $ 4.51   

Granted

     911,677      $ 15.02   

Forfeited

     (6,800   $ 4.13   

Vested or restrictions lapsed

     (1,551,242    $ 4.08   
  

 

 

   

Outstanding, September 30, 2012

     2,138,661      $ 9.31